source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Pulse2 | 2020-11-11 17:18:51 | https://pulse2.com/abbv-stock-nyse-abbvie-price-120-target-by-bernstein/ | The stock price of biopharmaceutical company AbbVie Inc (NYSE: ABBV) has received a target price of $120. These are the details. | ABBV Stock Price: $120 Target By Bernstein | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2020-11-10 19:30:58 | https://www.youtube.com/watch?v=9t19zL3tjCU | CNBC's Kelly Evans talks with Ronny Gal of Bernstein to discuss how to invest in health care and pharma stocks right now. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/Subs... | Why these biotech, pharma stocks have more upside: Analyst | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Insider Monkey | 2020-11-10 12:35:45 | https://www.insidermonkey.com/blog/5-leading-healthcare-stocks-surging-on-pent-up-demand-889339/ | As Mr. Valuation, I find myself constantly reminding investors that value investing requires patience. However, value investing also requires the willingness to get your money in front of attractive valuation when it is discovered. Trying to time your purchases perfectly can just as easily cause you to miss out on sign... | 5 Leading Healthcare Stocks Surging On Pent-Up Demand | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-11-10 06:29:16 | https://seekingalpha.com/article/4387478-glaxosmithkline-abbvie-choices-in-high-yield-pharma | GSK and ABBV are both attractively valued and high-yield picks available in the pharma space, discounted for their respective generics-eroded segments. We think that neither is a bad option in the long term, but would opt for GSK due to its lesser focus on oncology, a market that is becoming more and more crowded. | GlaxoSmithKline Or AbbVie: Choices In High-Yield Pharma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-11-09 17:36:24 | https://seekingalpha.com/article/4387271-abbvie-delivering-yet-another-double-digit-dividend-increase | AbbVie delivered yet another robust dividend increase, building on its dividend increase streak since it was spun off from Abbott Laboratories in 2013. AbbVie's operating fundamentals have remained strong despite COVID-19, with the company posting 13.2% YTD YoY adjusted diluted EPS growth. | AbbVie: Delivering Yet Another Double-Digit Dividend Increase | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2020-11-09 12:27:53 | https://investorplace.com/2020/11/blue-chip-stocks-you-can-count-on-in-todays-volatile-economy/ | Blue-chip stocks can generate large returns over time, making for great investments in a turbulent economy. Here are my top 7 picks. | 7 Stable Blue-Chip Stocks for Today's Volatile Economy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-11-08 07:06:16 | https://seekingalpha.com/article/4386627-92-stock-rose-portfolio-october-update-and-quality-evaluation-buy-list | 28 dividend payments brought income up delightfully by 10.2% from 2019 and up 11.7% from July 2020. Scary is the total portfolio value is down year to date by 10.2% including dividends and option cash with 2.4% of it just from October. | The 92 Stock Rose Portfolio October Update And Quality Evaluation Buy List | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-11-05 23:09:58 | https://seekingalpha.com/article/4385631-5-leading-healthcare-stocks-surging-on-pent-up-demand | The primary message behind this article is that value is worth waiting for, especially when a dividend is associated. Several high-quality companies in these subsectors posted strong price advances. | 5 Leading Healthcare Stocks Surging On Pent-Up Demand | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-11-05 04:46:03 | https://seekingalpha.com/article/4385154-65-november-dividend-aristocrats | "S&P 500® Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years."---us.spindices.com. The 65 Aristocrats of November 2020 represent ten of eleven Morningstar Sectors (no Technology). Broker targeted-top-ten net-gainers ranged 19.36%-45.91% topped... | 65 November Dividend Aristocrats | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2020-11-04 12:46:29 | https://247wallst.com/healthcare-business/2020/11/04/6-health-care-stocks-that-won-massively-from-the-2020-election/ | Making predictions about the winners and losers of an election is a hard job. After all, the pollsters cannot ever seem to get their polling correct. | 6 Health Care Stocks That Won Massively From the 2020 Election | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2020-11-04 08:53:53 | https://www.investors.com/news/technology/abbvie-stock-leasd-pack-biotech-stock-gains-republicans-could-retain-senate-majority/ | While the presidential race is undecided awaiting final results from key states, it appears Republicans could retain control of the Senate, and AbbVie stock and other biotech stocks rose. The post Republican Hold On Senate Seen As Plus For Drug Companies appeared first on Investor's Business Daily. | Republican Hold On Senate Seen As Plus For Drug Companies | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2020-11-02 07:00:00 | https://www.fool.com/investing/2020/11/02/3-top-stocks-with-high-dividend-yields/ | These three investments provide dividends of at least 4%, along with growth potential and a safe payout ratio. | 3 Top Stocks With High Dividend Yields | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2020-11-01 14:30:23 | https://www.gurufocus.com/news/1272638/pounding-the-table-for-abbvie | AbbVie Inc. (NYSE:ABBV), a name I have felt is undervalued for some time, reported third-quarter earnings results Friday morning that easily topped Wall Street's estimates. The company also gave yet another double-digit dividend increase. | Pounding the Table for AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-10-30 16:17:13 | https://seekingalpha.com/article/4383381-abbvie-inc-s-abbv-ceo-rick-gonzalez-on-q3-2020-results-earnings-call-transcript | AbbVie Inc.'s (ABBV) CEO Rick Gonzalez on Q3 2020 Results - Earnings Call Transcript | AbbVie Inc.'s (ABBV) CEO Rick Gonzalez on Q3 2020 Results - Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2020-10-30 14:18:00 | https://www.fool.com/investing/2020/10/30/how-abbvie-beat-expectations-in-q3/ | A strong performance from Humira was a big factor in the pharmaceutical company's success. | How AbbVie Beat Expectations in Q3 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2020-10-30 12:10:17 | https://investorplace.com/2020/10/abbvie-earnings-news-q3-highlights/ | AbbVie (ABBV) news for Friday includes results from the biopharmaceutical company's earnings report for the third quarter of 2020. The post AbbVie News: 5 Things for ABBV Investors to Know About Q3 appeared first on InvestorPlace. | AbbVie News: 5 Things for ABBV Investors to Know About Q3 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2020-10-30 08:05:32 | https://www.marketwatch.com/story/abbvie-beats-earnings-expectations-raises-its-outlook-and-boosts-dividend-2020-10-30 | Shares of AbbVie Inc. gained 0.2% in premarket trading Friday, after the biopharmaceutical and health care company reported third-quarter earnings that beat expectations, raised its full-year outlook and boosted its dividend by 10%. Net income rose to $2.31 billion, or $1.29 a share, from $1.88 billion, or $1.26 a shar... | AbbVie beats earnings expectations, raises its outlook and boosts dividend | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2020-10-30 08:03:33 | https://www.investors.com/news/technology/abbvie-earnings-humira-sales-abbv-stock/ | AbbVie earnings topped third-quarter views, helped by rising Humira sales. ABBV stock rose modestly before Friday's market open. | AbbVie Earnings Top Views On Rising Humira Sales | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2020-10-30 07:53:00 | https://www.reuters.com/article/us-abbvie-results/abbvie-raises-2020-profit-forecast-as-covid-19-hit-eases-idUSKBN27F1P1 | Drugmaker AbbVie Inc posted better-than-expected quarterly sales and raised its full-year adjusted profit forecast on Friday, as demand for its Botox and other treatments showed signs of recovery from the COVID-19 pandemic hit. | AbbVie raises 2020 profit forecast as COVID-19 hit eases | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2020-10-30 07:00:00 | https://www.fool.com/investing/2020/10/30/2-no-brainer-dividend-stocks-yielding-more-than-4/ | These two drugmakers are unlikely to slash or suspend their dividend payments -- even in the midst of a recession. | 2 No-Brainer Dividend Stocks Yielding More Than 4% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2020-10-29 02:05:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-new-analyses-from-pivotal-phase-3-studies-for-rinvoq-upadacitinib-in-atopic-dermatitis-301162496.html | NORTH CHICAGO, Ill., Oct. 29, 2020 /PRNewswire/ -- Late-breaking data analyses to be presented by AbbVie (NYSE: ABBV) at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadacitinib (15... | AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ (upadacitinib) in Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2020-10-28 15:45:44 | https://www.gurufocus.com/news/1269573/top-5-trades-of-the-eaton-vance-worldwide-health-sciences-fund | The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the third quarter of the year earlier this week. | Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2020-10-28 08:59:39 | https://investorplace.com/2020/10/7-cutting-edge-biotech-stocks-for-tomorrow/ | Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side. | 7 Cutting-Edge Biotech Stocks for Tomorrow | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-10-27 12:32:43 | https://seekingalpha.com/article/4381680-7-high-yield-and-high-growth-undervalued-dividend-stocks-to-buy-now | It is the combination of dividend yield and dividend growth which creates the magic of dividend investing. Combining high yield and high growth can have dramatic impacts on your income. | 7 High-Yield And High-Growth Undervalued Dividend Stocks To Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2020-10-27 06:12:00 | https://www.fool.com/investing/2020/10/27/3-stocks-you-can-still-buy-on-sale-in-a-ridiculous/ | And they all offer attractive dividends, too. | 3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-10-26 09:30:25 | https://seekingalpha.com/article/4381268-inexpensive-abbvies-high-dividend-yield-makes-buy | AbbVie is seeing success with new drugs. The company offers an attractive dividend yield and trades at a low valuation. | Inexpensive AbbVie's High Dividend Yield Makes It A Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-10-25 06:52:37 | https://seekingalpha.com/article/4381191-15-of-39-kiplinger-analyst-favorite-october-dividend-treats | In October and July Kiplinger Today listed Analyst and Kiplinger favorite dividend stocks. Analyst October favorites numbered 25, plus 15 from Kiplinger, with one repeated left 39 total. These 39 stocks ranged 1.50% to 10.11% in annual-yield and ranged 2.49% to 87.04% in one-year price-target-upsides per brokers 10/22/... | 15 Of 39 Kiplinger/Analyst Favorite October Dividend Treats | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-10-22 20:18:43 | https://seekingalpha.com/article/4380720-13-of-56-outstanding-dividend-stocks-stand-tall-for-november | From May to July, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. | 13 Of 56 Outstanding Dividend Stocks Stand Tall For November | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-10-20 23:41:35 | https://seekingalpha.com/article/4380120-abbvie-stock-will-break-100-management-and-market-are-on-page | AbbVie stock looked to have strong momentum in July, but Q2 results triggered a slide from $100, to $84 at the the time of writing. | AbbVie: Stock Will Break $100 Once Management And Market Are On Same Page (NYSE:ABBV) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-10-19 00:00:00 | https://www.businesswire.com/news/home/20201019005416/en/Antiviral-Drugs-Market-will-Exhibit-Neutral-Impact-during-2020-2024-Growing-Cases-of-Viral-Infections-to-Improve-the-Market-Growth-Technavio | The Global Antiviral Drugs Market will grow by USD 43.37 bn during 2020-2024 | Antiviral Drugs Market will Exhibit Neutral Impact during 2020-2024 | Growing Cases of Viral Infections to Improve the Market Growth | Technavio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
https://investorplace.com | 2020-10-16 09:16:53 | https://investorplace.com/2020/10/5-high-yield-stocks-abbv-enb-pm-unm-ibm-for-5-plus-dividend-payouts/ | Times have been tough lately for income investors, but these high-yield stocks whose dividends are safe remain worth a second look. | 5 High-Yield Stocks for 5%-Plus Dividend Payouts | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-10-15 08:16:20 | https://seekingalpha.com/article/4379160-buy-abbvie-raises-dividends-again | AbbVie has multiple product launches in 2021 that will bring billions more in revenue. Strong free cash flow available for a dividend hike. | Buy AbbVie Before It Raises Dividends Again (NYSE:ABBV) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-10-14 00:00:00 | https://www.businesswire.com/news/home/20201014005074/en/UCL-tests-prove-Airlite-paint-kills-coronaviruses | UCL has tested a paint from Airlite to prove is can kill strains of coronavirus.
Grosvenor Britain & Ireland have made Airlite its paint of choice | UCL tests prove Airlite paint kills coronaviruses | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-10-13 21:47:17 | https://seekingalpha.com/article/4378938-50-october-dividend-stocks-billionaires-love | Kiplinger Investing publishes opportune stock and fund lists for investors online. This Billionaire List by Dan Burrows, first published on 9/4/20, was updated on 10/9/20. | 50 October Dividend Stocks Billionaires Love | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-10-10 17:43:38 | https://seekingalpha.com/article/4378467-65-dividend-aristocrats-optimal-october-outcomes | S&P 500 Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years. - us.spindices.com. | 65 Dividend Aristocrats Optimal October Outcomes | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
https://www.thelincolnianonline.com | 2020-10-09 07:40:57 | https://www.thelincolnianonline.com/2020/10/09/trust-co-of-oklahoma-takes-487000-position-in-abbvie-inc-nyseabbv.html | Trust Co. of Oklahoma bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,555 shares of the company’s stock, valued at approximately $487,000. Several other large investors have also boug... | Trust Co. of Oklahoma Takes $487,000 Position in AbbVie Inc. (NYSE:ABBV) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-10-09 00:00:00 | https://www.businesswire.com/news/home/20201009005248/en/Ophthalmology-Therapeutics-Market-Increasing-Prevalence-of-Eye-Diseases-to-Boost-the-Market-Growth-Technavio | The Global Ophthalmology Therapeutics Market will grow by USD 10.42 bn during 2020-2024 | Ophthalmology Therapeutics Market | Increasing Prevalence of Eye Diseases to Boost the Market Growth | Technavio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-08 09:34:46 | https://www.marketwatch.com/press-release/the-global-active-pharmaceutical-ingredients-market-is-projected-to-reach-usd-2483-billion-by-2025-from-usd-1873-billion-in-2020-at-a-cagr-of-58-2020-10-08 | New York, Oct 08, 2020 (GLOBE NEWSWIRE via COMTEX) --
New York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report... | The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-10-08 08:24:51 | https://seekingalpha.com/article/4378099-33-dividend-stocks-fit-for-times-october-update | Kiplinger listed five sets of dividend stocks qualified to survive the COVID-19 pandemic. Barron's weekly added one more. | The 33 Dividend Stocks Fit For Our Times October Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-10-07 19:36:59 | https://seekingalpha.com/article/4378045-dividend-growth-portfolio-q3-update-28-holdings-16-sells-12-buys-3_89-yield | I received $67.56 in dividends for the quarter compared to $23.17 for Q3 of 2019. Hitting new highs in dividend income. | My Dividend Growth Portfolio Q3 Update: 28 Holdings, 16 Sells, 12 Buys, 3.89% Yield | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-07 06:29:12 | https://www.marketwatch.com/press-release/immunotherapy-drugs-market-report-analysis-share-revenue-growth-rate-with-forecast-overview-2020-10-07 | Oct 07, 2020 (AmericaNewsHour) --
This market research report includes a detailed segmentation of the global immunotherapy drugs market by drug type... | Immunotherapy drugs market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-07 06:01:34 | https://www.marketwatch.com/press-release/hepatocellular-carcinoma-drugs-market-size-share-2020-global-business-growth-trend-segmentation-top-key-players-analysis-industry-opportunities-and-forecast-to-2024-2020-10-07 | Oct 07, 2020 (The Expresswire) --
Global "Hepatocellular Carcinoma Drugs Market" 2020 provides strong industry focus with top Countries by key... | Hepatocellular Carcinoma Drugs Market Size, Share 2020 Global Business Growth, Trend, Segmentation, Top Key Players Analysis Industry, Opportunities and Forecast to 2024 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-05 10:48:31 | https://www.marketwatch.com/press-release/transplantation-market-growth-competitive-landscape-segment-forecasts-and-regional-outlook-2020---2027-2020-10-05 | Oct 05, 2020 (Profound via COMTEX) --
The study offers valuable information about the global Transplantation market to illustrate how the market would grow... | Transplantation Market Growth, Competitive Landscape, Segment Forecasts and Regional Outlook 2020 - 2027 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-05 10:09:38 | https://www.marketwatch.com/press-release/drugs-for-hiv-market-2020-comprehensive-analysis-top-countries-data-market-size-future-estimations-growth-drivers-and-forecast-to-2026-2020-10-05 | Oct 05, 2020 (The Expresswire) --
The Global "Drugs for HIV Market" is anticipated to rise at a considerable rate during the forecast period, between 2020... | Drugs for HIV Market 2020 : Comprehensive Analysis, Top Countries Data, Market Size, Future Estimations, Growth Drivers and Forecast to 2026 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-05 07:30:19 | https://www.marketwatch.com/press-release/microbiome-therapeutics-market-2020-industry-size-share-regional-growth-analysis-share-trends-and-forecast-2026-2020-10-05 | Oct 05, 2020 (The Expresswire) --
Microbiome is one of the fastest growing fields in biology. Fortune Business Insights, in a report titled “Microbiome... | Microbiome Therapeutics Market 2020 Industry Size, Share, Regional Growth Analysis, Share, Trends and Forecast 2026 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-05 06:37:30 | https://www.marketwatch.com/press-release/drugs-for-hiv-market-2020---global-industry-research-update-future-scope-size-estimation-revenue-pricing-trends-regional-outlook-and-forecast-to-2026-2020-10-05 | Oct 05, 2020 (The Expresswire) --
The latest report published with an innovative statistics of the market titled as Drugs for HIV Marketacknowledges Size... | Drugs for HIV Market 2020 - Global Industry Research Update, Future Scope, Size Estimation, Revenue, Pricing Trends, Regional Outlook and Forecast to 2026 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-05 06:37:27 | https://www.marketwatch.com/press-release/bi-specific-antibodies-therapy-market-2020-global-industry-trends-growth-share-size-and-2026-forecast-research-report-2020-10-05 | Oct 05, 2020 (The Expresswire) --
The latest report published with an innovative statistics of the market titled as Bi-Specific Antibodies Therapy... | Bi-Specific Antibodies Therapy Market: 2020 Global Industry Trends, Growth, Share, Size And 2026 Forecast Research Report | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
investing | 2020-10-05 00:00:00 | https://www.investing.com/news/coronavirus/hiv-treatment-has-no-benefit-for-hospitalised-covid19-patients-study-2316322 | HIV treatment has no benefit for hospitalised COVID-19 patients: study | HIV treatment has no benefit for hospitalised COVID-19 patients: study | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-10-03 14:55:07 | https://seekingalpha.com/article/4377462-regenxbio-advances-clinical-program-and-news-good-bad-and-ugly-of-biopharma | Regenxbio announces expansion of RGX-121 clinical program. AbbVie announces pulling Fibristal from the Canadian market. | Regenxbio Advances Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:RGNX) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-01 12:34:30 | https://www.marketwatch.com/press-release/global-fabry-disease-therapeutic-market-size-top-countries-statistics-scope-sales-growth-drivers-opportunities-industry-trends-and-forecasts-to-2026-2020-10-01 | Oct 01, 2020 (The Expresswire) --
“Fabry Disease Therapeutic Market" report provides a detailed evaluation of the market by highlighting information on... | Global Fabry Disease Therapeutic Market Size, Top Countries Statistics, Scope, Sales, Growth Drivers, Opportunities, Industry Trends and Forecasts to 2026 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-10-01 11:44:36 | https://www.marketwatch.com/press-release/seasonal-affective-disorder-therapeutics-market-2020-disclosing-latest-trends-and-advancement-outlook-2025-2020-10-01 | Oct 01, 2020 (Market Insight Reports) --
The Seasonal Affective Disorder Therapeutics Market as of late Published Global Market look into study with in... | Seasonal Affective Disorder Therapeutics Market 2020 Disclosing Latest Trends and Advancement Outlook 2025 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-09-30 12:30:15 | https://www.marketwatch.com/press-release/solving-one-of-the-largest-drivers-of-disease-inflammation-2020-09-30 | NEW YORK, Sept. 30, 2020 /PRNewswire via COMTEX/ --
NEW YORK, Sept. 30, 2020 /PRNewswire/ -- Inflammation typically occurs in the body as a natural response... | Solving One of the Largest Drivers of Disease: Inflammation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-09-28 00:00:00 | https://www.businesswire.com/news/home/20200928005613/en/Global-Anti-Viral-Therapies-Market-Forecast-to-2027---COVID-19-Impact-and-Analysis---ResearchAndMarkets.com | The | Global Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-09-26 00:00:00 | https://www.businesswire.com/news/home/20200925005337/en/Eczema-Therapeutics-Market--Roadmap-for-Recovery-from-COVID-19-Geopolitical-Uncertainties-to-Boost-the-Market-Growth-Technavio | The Global Eczema Therapeutics Market will grow by USD 3.60 bn during 2020-2024 | Eczema Therapeutics Market- Roadmap for Recovery from COVID-19 | Geopolitical Uncertainties to Boost the Market Growth | Technavio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-09-25 03:41:05 | https://seekingalpha.com/article/4376242-56-outstanding-dividend-stocks-for-october-from-kiplinger | From May to July Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. | 56 Outstanding Dividend Stocks For October From Kiplinger | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-09-23 00:00:00 | https://www.businesswire.com/news/home/20200922005958/en/Anti-inflammatory-Therapeutics-Market--Roadmap-for-Recovery-from-COVID-19Increase-In-Prevalence-Of-IMID-to-boost-the-Market-Growth-Technavio | The Global Anti-inflammatory Therapeutics Market will grow by USD 30.62 bn during 2020-2024 | Anti-inflammatory Therapeutics Market- Roadmap for Recovery from COVID-19|Increase In Prevalence Of IMID to boost the Market Growth | Technavio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-09-22 12:30:10 | https://seekingalpha.com/article/4375609-abbvie-i-dont-wanna-miss-this-thing | 2020 is shaping up to be another record year for AbbVie. Six months into the pandemic, AbbVie has mastered the crisis better than expected and once again demonstrated the power of its strong and resilient portfolio. | AbbVie: I Don't Wanna Miss This Thing (NYSE:ABBV) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-09-19 00:00:00 | https://www.businesswire.com/news/home/20200918005327/en/COVID-19-Recovery-Analysis-Monoclonal-Antibodies-Market-Advent-of-Low-priced-Biosimilar-Monoclonal-Antibodies-to-Boost-the-Market-Growth-Technavio | The Global Monoclonal Antibodies Market will grow by $ 54.55 bn during 2020-2024 | COVID-19 Recovery Analysis: Monoclonal Antibodies Market | Advent of Low-priced Biosimilar Monoclonal Antibodies to Boost the Market Growth | Technavio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-09-18 17:54:57 | https://seekingalpha.com/article/4375196-50-billionaire-holdings-27-pay-dividends-2-to-buy-in-september | Kiplinger Investing publishes opportune stock and fund lists for investors online. This Billionaire List by Dan Burrows, first published 9/4/20, was updated 9/16/20. | 50 Billionaire Holdings, 27 Pay Dividends, 2 To Buy In September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-09-18 09:35:28 | https://seekingalpha.com/article/4375084-abbvie-still-20-undervalued-high-yielding-buy | I wrote about AbbVie about a year ago, and have mentioned the company in many of my monthly and undervaluation-focused articles. | AbbVie - Still A 20% Undervalued, High-Yielding Buy (NYSE:ABBV) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha | 2020-09-17 21:55:02 | https://seekingalpha.com/article/4375017-interest-rates-and-impact-on-stock-values | When it comes to long-term returns and risk, valuation matters, and it matters a lot. People believe that lower interest rates justify higher valuations because equities become the only game in town when interest rates are as low as they are today. | Interest Rates And Their Impact On Stock Values | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-09-17 00:00:00 | https://www.businesswire.com/news/home/20200917005067/en/Intrauterine-Contraceptive-Devices-IUD-Market-COVID-19-Business-Continuity-Plan-Evolving-Opportunities-with-AbbVie-Inc.-and-Bayer-AG-Technavio | The Global Intrauterine Contraceptive Devices (IUD) Market will grow by $ 597.40 mn during 2020-2024 | Intrauterine Contraceptive Devices (IUD) Market: COVID-19 Business Continuity Plan | Evolving Opportunities with AbbVie Inc. and Bayer AG | Technavio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
http://www.stocksequity.com | 2020-09-16 03:26:35 | http://www.stocksequity.com/active-stocks/is-the-stock-worthy-chf-solutions-inc-nasdaqchfs-abbvie-inc-nyseabbv/ | CHF Solutions, Inc. (NASDAQ:CHFS) with the stream of 8.97% also noticed, India AbbVie Inc. (NYSE:ABBV) encountered a rapid change of 0.46% in the last hour of Tuesday’s trading session. CHF … | Is The Stock Worthy? CHF Solutions, Inc. (NASDAQ:CHFS), AbbVie Inc. (NYSE:ABBV) - Stocks Equity | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-15 07:34:24 | https://seekingalpha.com/article/4374345-abbvie-time-is-now | ABBV has sold off in recent weeks. Biotechs are starting to outperform. | AbbVie: The Time Is Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-15 01:00:49 | https://seekingalpha.com/article/4374305-dividend-aristocrats-see-6-star-september-selections | S&P 500® Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years.---us.spindices.com. | Dividend Aristocrats See 6 Star September Selections | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-13 10:32:46 | https://seekingalpha.com/article/4373934-dividend-income-update-august-2020 | August was a little underwhelming for me as my income dropped a bit, but this was due to sales made last year. | Dividend Income Update: August 2020 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
cnbc | 2020-09-11 12:00:02 | https://www.cnbc.com/2020/09/11/pharmacabbvie-employees-raise-safety-concerns-with-return-to-work-plans.html | Even if employees have demonstrated an ability to do their jobs from home, the company expects them to report to the office to foster creativity and innovation under its phased-in return-to-work plan. | Drugmaker AbbVie pressures reluctant employees to return to work, raising safety questions | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-10 11:30:00 | https://seekingalpha.com/article/4373445-when-tech-stocks-fail-you-choose-5-undervalued-low-risk-dividend-aristocrats | Tech clearly has been the winner so far in 2020, thanks to positive sentiment. Much of these gains were driven by multiple expansion, not by underlying earnings growth. | When Tech Stocks Fail You, Choose These 5 Undervalued, Low-Risk Dividend Aristocrats | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-10 07:43:33 | https://seekingalpha.com/article/4373482-20-stocks-i-hope-to-buy-during-next-market-sell-off-high-yield-edition | In this article, I use yield thresholds, instead of valuation multiples, to arrive at recession wish list buy targets. | 20 More Stocks I Hope To Buy During The Next Market Sell-Off (High Yield Edition) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-09 05:52:27 | https://seekingalpha.com/article/4373196-september-2020-stocks-financials-real-estate-industrials-and-pharma | The time has come once again to look at what sort of companies you'll want to be buying, this time as we move into September of 2020. | September 2020 Stocks - Financials, Real Estate, Industrials, IT And Pharma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-09 03:52:05 | https://seekingalpha.com/article/4373184-91-kiplinger-most-reliable-dividend-stocks-on-earth-september-update | Kiplinger insights for investors online, offered this list of 91 Top Dividend Stocks From Around The World July 13. | A 91 Kiplinger 'Most Reliable Dividend Stocks On Earth' September Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-08 04:46:29 | https://seekingalpha.com/article/4372972-abbvie-i-mab-cancer-deal-and-news-good-bad-and-ugly-of-biopharma | AbbVie inks multi-billion cancer deal with I-Mab. Chi-Med begins global phase III trial of cancer treatment. | AbbVie I-Mab Cancer Deal, And Other News: The Good, Bad And Ugly Of Biopharma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-07 06:59:02 | https://seekingalpha.com/article/4372875-nicholas-wards-dividend-growth-portfolio-august-2020-review | My passive income increased 15.9% year over year. My portfolio posted gains of 8.6% during August. | Nicholas Ward's Dividend Growth Portfolio: August 2020 Review | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-07 01:15:15 | https://seekingalpha.com/article/4372848-33-dividend-stocks-fit-for-covidminus-19-times-september-update | Kiplinger listed five sets of dividend stocks qualified to survive the Covid-19 pandemic. Barron's weekly added one more. | 33 Dividend Stocks Fit For COVID-19 Times: A September Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-06 22:50:57 | https://seekingalpha.com/article/4372844-calm-down-this-time-wont-be-different | The market closed down last week. Investors are getting jittery. | Calm Down: This Time Won't Be Different | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-06 12:21:27 | https://seekingalpha.com/article/4372814-week-in-review-i-mab-partners-cd47-abbvie-in-2-billion-deal | Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement. | Week In Review: I-Mab Partners CD47 With AbbVie In $2 Billion Deal | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-05 09:37:14 | https://seekingalpha.com/article/4372749-august-2020-dividend-portfolio-update | Markets were racing to all-time highs in August fueled by technology stocks and the mega caps. I am continuing my monthly investment plans and suspiciously follow the massive rally in technology stocks. | August 2020 Dividend Portfolio Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-04 02:45:56 | https://seekingalpha.com/article/4372553-dividend-growth-portfolio-august-review-38-holdings-no-trades | I received $768 in August, which was down from May and down from August 2019. I made no trades over the month as stocks continue their meteoric rise. | My Dividend Growth Portfolio August Review: 38 Holdings, No Trades | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-04 00:54:37 | https://seekingalpha.com/article/4372548-humira-battles-abbvies-upa-versus-gileads-filgo-redux | AbbVie's upa (now RINVOQ) has lived up to my expectations. Filgo, which many had pegged as the superior of the two, has faltered on the way to the bout. | Humira Battles: AbbVie's Upa Versus Gilead's Filgo-Redux | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-03 18:47:12 | https://seekingalpha.com/article/4372506-sell-off-accelerates-what-to-now | The S&P 500's sell-off accelerates. The best sectors and stocks to consider when it bottoms. | The Sell-Off Accelerates, What To Do Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-03 18:36:56 | https://seekingalpha.com/article/4372503-rose-89-stock-portfolio-august-2020-update | 20 company dividend payments were received, increasing income by 32%, reversing the low income of July, making Q3 up 2.5% from April and May of Q2. | The Rose 89 Stock Portfolio August 2020 Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-03 13:06:26 | https://seekingalpha.com/article/4372393-august-2020-portfolio-update-cash-investments | The time has come to look over August's investments and dividends. Markets continue to recover, though some sectors remain in turmoil. | August 2020 Portfolio Update - More Cash, More Investments | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-09-03 07:50:44 | https://seekingalpha.com/article/4372303-blue-chip-drip-portfolio-august-dividends-covered-call-income | August dividend income was stronger than anticipated, considering the widespread cuts and our recent stock liquidation to buy a home. | Blue Chip DRiP Portfolio: August Dividends + Covered Call Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-31 10:00:00 | https://seekingalpha.com/article/4371659-abbvie-dividend-growth-stock-trading-big-discount | ABBV shares are trading at a forward earnings multiple of 7.7x. The company has a loaded pipeline and a slew of new drugs with HUGE potential. | AbbVie: Dividend Growth Stock Trading At A BIG Discount | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-30 05:38:52 | https://seekingalpha.com/article/4371532-56-kiplinger-outstanding-dividend-stocks-for-september | Kiplinger Today in July listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. | 56 Kiplinger Outstanding Dividend Stocks For September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-30 04:22:25 | https://seekingalpha.com/article/4371529-beigene-covidminus-19-deal-and-news-good-bad-and-ugly-of-biopharma | BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies. UroGen flunks Phase 2 RTGel combo study. | BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-29 07:58:36 | https://seekingalpha.com/article/4371505-why-i-bought-abbvie-despite-43-appreciation-this-year | AbbVie faces some looming questions about the loss of mega-blockbuster Humira in 2023, and a highly leveraged balance sheet. | Why I Bought AbbVie Despite 43% Appreciation This Year | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-28 15:10:10 | https://seekingalpha.com/article/4371440-you-can-still-buy-industrial-and-technology-stocks-risk-controls-are-key | You Can Still Buy Industrial And Technology Stocks, But Risk Controls Are Key | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News | |
seekingalpha.com | 2020-08-28 09:36:21 | https://seekingalpha.com/article/4371338-tracking-dan-loebs-third-point-portfolio-q2-2020-update | Dan Loeb's 13F portfolio value increased from $6.27B to $7.30B this quarter. The number of positions increased from 30 to 36. | Tracking Dan Loeb's Third Point Portfolio - Q2 2020 Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-08-27 11:05:00 | https://www.marketwatch.com/story/dont-settle-for-skimpy-bond-yields-and-make-dividend-stocks-your-best-income-play-fixed-income-veteran-says-2020-08-27 | The fixed-income market ‘is as much of a challenge as I have seen in 41 years,’ says Dan Genter, CEO of RNC Genter Capital Management. | Don’t settle for skimpy bond yields and make dividend stocks your best income play, fixed-income veteran says | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-08-27 00:00:00 | https://www.businesswire.com/news/home/20200827005606/en/Global-Immunosuppressant-Drugs-Market-2020-2025-COVID-19-Impact | The | Global Immunosuppressant Drugs Market 2020-2025 with COVID-19 Impact Analysis and Profilings of 16 Major Players - ResearchAndMarkets.com | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-25 16:31:14 | https://seekingalpha.com/article/4370720-xlv-healthcare-sector-is-underestimated | XLV is a diversified healthcare ETF including some of the larger caps in the S&P 500. Despite knowing some upside, it has been underperforming when comparing with peers. | XLV: The Healthcare Sector Is Underestimated | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
marketwatch | 2020-08-25 11:17:00 | https://www.marketwatch.com/story/these-dividend-aristocrat-stocks-have-been-raising-their-dividends-for-decades-and-there-have-been-no-dividend-cuts-during-the-pandemic-2020-08-25 | Dozens of other S&P 500 companies, in contrast, have reduced their payouts. | These ‘Dividend Aristocrat’ stocks have been raising their dividends for decades, and there have been no dividend cuts during the pandemic | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
businesswire | 2020-08-25 00:00:00 | https://www.businesswire.com/news/home/20200825005524/en/Insights-Multiple-Sclerosis-Therapies-Global-Market-2027 | The | Insights on the Multiple Sclerosis Therapies Global Market to 2027 - Opportunity Analysis and Industry Forecast - ResearchAndMarkets.com | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-22 07:24:19 | https://seekingalpha.com/article/4370247-market-neutral-strategy-long-abbvie-short-gilead | With an overvalued stock market reaching for record high ratios vs. underlying business profits and sales, hedged long/short portfolio designs are worth consideration. | Market Neutral Strategy: Long AbbVie, Short Gilead | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-20 12:32:19 | https://seekingalpha.com/article/4369949-tracking-david-teppers-appaloosa-management-portfolio-q2-2020-update | David Tepper’s 13F portfolio value increased from $3.27B to $5.76B this quarter. Appaloosa added AT&T while increasing Alibaba Group Holdings during the quarter. | Tracking David Tepper's Appaloosa Management Portfolio - Q2 2020 Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
seekingalpha.com | 2020-08-20 07:44:16 | https://seekingalpha.com/article/4369875-15-wonderful-blue-chip-buys-i-just-made-for-retirement-portfolio | The S&P 500 has ended its bear market, after seeing the greatest 100-day rally in history, and recovering new record highs just 104 trading days after March 23rd lows. | 15 Wonderful Blue-Chip Buys I Just Made For My Retirement Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-08-19 23:02:11 | https://finance.yahoo.com/news/3-strong-diverse-dividend-stocks-230211395.html | It might be best to find stable stocks that offer solid dividend yields. So let's examine three highly-ranked stocks from three different industries that fit the bill... | 3 Strong, Diverse Dividend Stocks to Buy with Market at New Highs | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-08-19 15:04:00 | https://finance.yahoo.com/m/d0f22b8d-f4dc-31a3-88f4-3dc45e3834b0/fda-denies-approval-for.html | Onlookers had been expecting a thumbs up for filgotinib. Now, that won't happen for at least another year. | FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-08-19 14:42:00 | https://finance.yahoo.com/m/1b3bd588-4a6e-368c-9cf9-17abfd08e20d/potential-gilead-blockbusters.html | The Food and Drug Administration rejected Gilead Sciences’ application for a would-be blockbuster arthritis drug Tuesday night, blindsiding investors. | Potential Gilead Blockbusters Were Rejected By the FDA. Why That’s the ‘Near-Worst-Case Scenario’ for the Stock. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.